Corvus Pharmaceuticals Inc (CRVS) is trading up at $10.65 (+5.97%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Operating income | −$37.0M | −$56.5M | −$49.2M | −$48.9M | −$43.8M | −$38.6M | −$32.6M | −$23.4M | −$27.5M | −$43.0M |
| Net income | −$36.4M | −$55.7M | −$46.9M | −$46.7M | −$6.00M | −$43.2M | −$41.3M | −$27.0M | −$62.3M | −$15.3M |
| EPS (diluted) | −$2.36 | −$2.72 | −$1.71 | −$1.59 | −$0.20 | −$1.03 | −$0.89 | −$0.56 | −$1.02 | −$0.53 |
| Balance sheet | ||||||||||
| Cash and equivalents | $5.05M | $45.1M | $39.2M | $5.15M | $16.5M | $63.5M | $13.2M | $12.6M | $8.74M | $4.58M |
| Total assets | $140.2M | $94.8M | $118.2M | $83.6M | $85.5M | $109.5M | $68.2M | $45.6M | $68.9M | $71.1M |
| Total liabilities | $7.35M | $9.94M | $7.90M | $12.5M | $13.4M | $12.3M | $12.1M | $6.87M | $36.3M | $9.91M |
| Shareholders' equity | $132.8M | $84.8M | $110.3M | $71.1M | $72.1M | $97.2M | $56.1M | $38.7M | $32.6M | $61.2M |
| Cash flow | ||||||||||
| Operating cash flow | −$27.9M | −$46.2M | −$41.0M | −$37.3M | −$34.8M | −$36.7M | −$27.0M | −$23.9M | −$25.4M | −$32.8M |
| Capital expenditure | $2.20M | $266.0K | $355.0K | $25.0K | $76.0K | $5.00K | $269.0K | $34.0K | — | $174.0K |
| Free cash flow | −$30.1M | −$46.5M | −$41.3M | −$37.3M | −$34.9M | −$36.7M | −$27.3M | −$24.0M | — | −$33.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$7.25M | −$8.11M | −$9.92M | −$10.3M | −$10.6M | −$12.2M | −$14.9M | −$19.3M |
| Net income | −$40.2M | −$12.1M | $15.2M | −$8.00M | −$10.2M | −$12.3M | −$13.7M | −$18.0M |
| EPS (diluted) | −$0.60 | −$0.23 | −$0.13 | −$0.10 | −$0.12 | −$0.18 | −$0.15 | −$0.19 |
| Balance sheet | ||||||||
| Cash and equivalents | $4.68M | $8.74M | $5.00M | $14.7M | $2.87M | $4.58M | $40.1M | $18.9M |
| Total assets | $58.8M | $68.9M | $59.4M | $89.5M | $80.5M | $71.1M | $253.2M | $239.3M |
| Total liabilities | $46.4M | $36.3M | $10.1M | $9.23M | $8.71M | $9.91M | $12.5M | $13.9M |
| Shareholders' equity | $12.4M | $32.6M | $49.3M | $80.2M | $71.8M | $61.2M | $240.7M | $225.3M |
| Cash flow | ||||||||
| Operating cash flow | −$6.32M | −$8.46M | −$8.26M | −$5.78M | −$9.57M | −$9.19M | −$10.4M | −$15.4M |
| Capital expenditure | — | — | $36.0K | $113.0K | $0 | $25.0K | $91.0K | $582.0K |
| Free cash flow | — | — | −$8.30M | −$5.89M | −$9.57M | −$9.22M | −$10.5M | −$16.0M |
From Corvus Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Corvus Pharmaceuticals Inc in our feed yet.